Last checked at 
10 Mar 2021 07:00
London, UK, 10 March 2021
Edison issues review on The Biotech Growth Trust (BIOG)
The Biotech Growth Trust (BIOG) generated another year of positive absolute and relative performance in 2020. Manager Geoff Hsu of global specialist healthcare investor OrbiMed Capital remains constructive on the outlook for biotech stocks, although he is mindful about the extended bull run in the US stock market. The manager is particularly encouraged by the high levels of biotech industry innovation; he believes that the favourable regulatory environment will continue and does not consider healthcare legislation to be a high priority for President Biden. Hsu comments that the biotech industry has 'come of age' over the last decade; he highlights the high number of initial public offerings (IPOs) in the sector, while the level of merger and acquisition (M&A) activity has remained robust despite the shift to working from home during the COVID-19 pandemic.
BIOG had been regularly trading close to NAV, but the discount has widened recently due to profit taking in the technology and biotech sectors. The trust's current 8.7% share price discount to cum-income NAV compares with the 2.5% to 5.8% range of average discounts over the last one, three, five and 10 years.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Mel Jenner +44 (0)20 3077 5720 investmenttrusts@edisongroup.com
Sarah Godfrey +44 (0)20 3681 2519 investmenttrusts@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv